Enteropathogen Changes After Rotavirus Vaccine Scale-up.


Journal

Pediatrics
ISSN: 1098-4275
Titre abrégé: Pediatrics
Pays: United States
ID NLM: 0376422

Informations de publication

Date de publication:
01 01 2022
Historique:
accepted: 14 10 2021
pubmed: 18 12 2021
medline: 18 1 2022
entrez: 17 12 2021
Statut: ppublish

Résumé

To inform next steps in pediatric diarrhea burden reduction by understanding the shifting enteropathogen landscape after rotavirus vaccine implementation. We conducted a case-control study of 1788 medically attended children younger than 5 years, with and without gastroenteritis, after universal rotavirus vaccine implementation in Peru. We tested case and control stools for 5 viruses, 19 bacteria, and parasites; calculated coinfection-adjusted attributable fractions (AFs) to determine pathogen-specific burdens; and evaluated pathogen-specific gastroenteritis severity using Clark and Vesikari scales. Six pathogens were independently positively associated with gastroenteritis: norovirus genogroup II (GII) (AF 29.1, 95% confidence interval [CI]: 28.0-32.3), rotavirus (AF 8.9, 95% CI: 6.8-9.7), sapovirus (AF 6.3, 95% CI: 4.3-7.4), astrovirus (AF 2.8, 95% CI: 0.0-4.0); enterotoxigenic Escherichia coli heat stable and/or heat labile and heat stable (AF 2.4, 95% CI: 0.6-3.1), and Shigella spp. (AF 2.0, 95% CI: 0.4-2.2). Among typeable rotavirus cases, we most frequently identified partially heterotypic strain G12P[8] (54 of 81, 67%). Mean severity was significantly higher for norovirus GII-positive cases relative to norovirus GII-negative cases (Vesikari [12.7 vs 11.8; P < .001] and Clark [11.7 vs 11.4; P = .016]), and cases in the 6- to 12-month age range relative to cases in other age groups (Vesikari [12.7 vs 12.0; P = .0002] and Clark [12.0 vs 11.4; P = .0016]). Norovirus is well recognized as the leading cause of pediatric gastroenteritis in settings with universal rotavirus vaccination. However, sapovirus is often overlooked. Both norovirus and sapovirus contribute significantly to the severe pediatric disease burden in this setting. Decision-makers should consider multivalent vaccine acquisition strategies to target multiple caliciviruses in similar countries after successful rotavirus vaccine implementation.

Identifiants

pubmed: 34918158
pii: 183843
doi: 10.1542/peds.2020-049884
pmc: PMC9647525
pii:
doi:

Substances chimiques

Rotavirus Vaccines 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : R21 AI099737
Pays : United States
Organisme : FIC NIH HHS
ID : R25 TW009340
Pays : United States

Informations de copyright

Some authors are military service members or employees of the US Government. This work was prepared as part of their official duties. Title 17 U.S.C. §105 provides that “Copyright protection under this title is not available for any work of the United states Government.” Title 17 USC §101 defines a US Government work as a work prepared by a military service member or employee of the US Government as part of that person’s official duties.

Déclaration de conflit d'intérêts

FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.

Références

J Glob Health. 2019 Dec;9(2):020805
pubmed: 31673349
J Med Virol. 2009 Feb;81(2):371-81
pubmed: 19107963
J Med Virol. 2006 Sep;78(9):1241-9
pubmed: 16847962
Am J Epidemiol. 1985 Nov;122(5):904-14
pubmed: 4050778
J Clin Virol. 2011 Jun;51(2):121-5
pubmed: 21514213
Clin Infect Dis. 2014 Feb;58(4):483-91
pubmed: 24300042
Arch Virol. 2004 Sep;149(9):1673-88
pubmed: 15593412
J Clin Virol. 2015 Jul;68:83-8
pubmed: 26071343
J Vis Exp. 2012 Jul 22;(65):
pubmed: 22898754
Bull U S Army Med Dep. 1948 Apr;8(4):326
pubmed: 18911509
J Med Virol. 2007 May;79(5):633-8
pubmed: 17387750
Eur J Clin Microbiol Infect Dis. 2010 Aug;29(8):955-60
pubmed: 20490883
Lancet. 1978 May 27;1(8074):1119-22
pubmed: 77415
J Med Virol. 2017 Oct;89(10):1775-1781
pubmed: 28500748
Clin Infect Dis. 2013 Jul;57(1):13-20
pubmed: 23487388
J Infect Dis. 2013 Sep 1;208(5):790-800
pubmed: 23757337
Genome Announc. 2017 Oct 26;5(43):
pubmed: 29074655
Arch Virol. 2012 Jan;157(1):135-9
pubmed: 21947565
Am J Trop Med Hyg. 2017 May;96(5):1097-1106
pubmed: 28167602
Clin Infect Dis. 2018 Jun 1;66(12):1858-1863
pubmed: 29309577
Lancet Glob Health. 2018 Dec;6(12):e1309-e1318
pubmed: 30287127
Einstein (Sao Paulo). 2015 Jul-Sep;13(3):435-40
pubmed: 26061078
J Clin Microbiol. 2016 Jun;54(6):1598-1604
pubmed: 27076657
J Infect Dis. 1999 May;179(5):1139-44
pubmed: 10191215
Am J Clin Nutr. 2019 Oct 1;110(4):1015-1025
pubmed: 31565748
Vaccine. 2008 Oct 29;26(46):5798-801
pubmed: 18786584
J Virol. 2007 Mar;81(5):2382-90
pubmed: 17166908
Virol Sin. 2020 Oct;35(5):501-516
pubmed: 32342286
Clin Infect Dis. 2016 May 15;62(10):1210-7
pubmed: 27013692
PLoS One. 2014 May 21;9(5):e98201
pubmed: 24849288
J Pediatr Gastroenterol Nutr. 2016 Nov;63(5):466-473
pubmed: 27347723
Lancet. 2013 Jul 20;382(9888):209-22
pubmed: 23680352
Lancet. 2017 Dec 17;388(10063):3027-3035
pubmed: 27839855
Lancet. 2016 Sep 24;388(10051):1291-301
pubmed: 27673470
Lancet Glob Health. 2015 Sep;3(9):e564-75
pubmed: 26202075
BMC Infect Dis. 2012 Sep 13;12:213
pubmed: 22974466
Clin Infect Dis. 2015 Aug 15;61(4):e20-5
pubmed: 25870322
Public Health Nutr. 2012 Sep;15(9):1603-10
pubmed: 22717390
J Med Virol. 2008 Aug;80(8):1489-96
pubmed: 18551614
Epidemiol Infect. 2012 Jan;140(1):74-7
pubmed: 21371364
J Clin Virol. 2012 Jun;54(2):162-7
pubmed: 22410133
J Med Virol. 2017 Feb;89(2):234-238
pubmed: 27420653
Curr Opin Infect Dis. 2015 Oct;28(5):408-16
pubmed: 26237546
PLoS One. 2015 Jul 10;10(7):e0131646
pubmed: 26161556
Emerg Infect Dis. 2002 May;8(5):508-13
pubmed: 11996687
Pediatrics. 2018 Jan;141(1):
pubmed: 29259078
Am J Trop Med Hyg. 2019 Sep;101(3):541-548
pubmed: 31392944

Auteurs

Sarah-Blythe Ballard (SB)

Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland.
Naval Medical Research Unit No. 6, Callao, Peru.

David Requena (D)

Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.

Holger Mayta (H)

Infectious Disease Research Laboratory, Department of Cellular and Molcular Sciences, Universidad Peruana Cayetano Heredia, Lima, Peru.
Asociación Benéfica PRISMA, Lima, Peru.

Gerardo J Sanchez (GJ)

Infectious Disease Research Laboratory, Department of Cellular and Molcular Sciences, Universidad Peruana Cayetano Heredia, Lima, Peru.

Maria G Oyola-Lozada (MG)

Infectious Disease Research Laboratory, Department of Cellular and Molcular Sciences, Universidad Peruana Cayetano Heredia, Lima, Peru.

Fabiola D Colquechagua Aliaga (FD)

Asociación Benéfica PRISMA, Lima, Peru.

Lilia Cabrera (L)

Asociación Benéfica PRISMA, Lima, Peru.

Macarena D Vittet Mondonedo (MD)

Infectious Disease Research Laboratory, Department of Cellular and Molcular Sciences, Universidad Peruana Cayetano Heredia, Lima, Peru.

Carmen Taquiri (C)

Infectious Disease Research Laboratory, Department of Cellular and Molcular Sciences, Universidad Peruana Cayetano Heredia, Lima, Peru.

Capt Drake H Tilley (CDH)

Naval Medical Research Unit No. 6, Callao, Peru.
Fleet Surgical Team SEVEN, Okinawa, Japan.

Cdr Mark P Simons (CMP)

Naval Medical Research Unit No. 6, Callao, Peru.

Rina A Meza (RA)

Naval Medical Research Unit No. 6, Callao, Peru.

Caryn Bern (C)

Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California.

Mayuko Saito (M)

Infectious Disease Research Laboratory, Department of Cellular and Molcular Sciences, Universidad Peruana Cayetano Heredia, Lima, Peru.
Department of Virology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Dante A Figueroa-Quintanilla (DA)

Instituto Nacional del Salud del Niño, Lima, Peru.

Robert H Gilman (RH)

Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
Infectious Disease Research Laboratory, Department of Cellular and Molcular Sciences, Universidad Peruana Cayetano Heredia, Lima, Peru.
Asociación Benéfica PRISMA, Lima, Peru.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH